Abstract
Single-chain Fv molecules in monovalent (sFv) and divalent [(sFv')2] forms exhibit highly specific tumor targeting in mice as a result of their small size and rapid systemic clearance. As a consequence, there is a rapid reversal of the sFv blood/tumor gradient, resulting in diminished retention of sFv species in tumors. In this report we investigate two distinct strategies, dose escalation and repetitive intravenous (i.v.) dosing, aiming to increase the absolute selective retention of radiolabeled anti-c-erbB-2125I-741F8 (sFv')2 in c-erbB-2-overexpressing SK-OV-3 tumors in mice with severe combined immunodeficiency (SCID). A doseescalation strategy was applied to single i.v. injections of125I-741F8 (sFv')2. Doses from 50 μg to 1000 μg were administered without a significant decrease in tumor targeting or specificity. High doses resulted in large increases in the absolute retention of125I-741F8 (sFv')2. For example, raising the administered dose from 50 μg to 1000 μg increased the tumor retention 24 h after injection from 0.46 μg/g to 9.5 μg/g, and resulted in a net increase of greater than 9 μ/g. Over the same dose range, the liver retention rose from 0.06 μg/g to 1 μg/g, and resulted in a net increase of less than 1 μg/g. The retention of 9.5 μg/g in tumor 24 h fllowing the 1000-μg dose of (sFv')2 was comparable to that seen 24 h after a 50-μg dose of125I-741F8 IgG, indicating that the use of large doses of (sFv')2 may partially offset their rapid clearance. When two doses were administered by i.v. injection 24 h apart, the specificity of delivery to tumor observed after the first dose was maintained following the second injection. Tumor retention of125I-741F8 (sFv')2 was 0.32 μg/g at 24 h and 0.22 μg/g at 48 h following a single injection of 20 μg/g, while 0.04 μg/ml and 0.03 μg/ml were retained in blood at the same assay times. After a second 20-μg injection at the 24-h assay time, tumor retention increased to 0.49 μg/g, and blood retention was 0.06 μg/ml, at the 48-h point. These results suggest that multiple high-dose administrations of radiolabeled 741F8 (sFv')2 may lead to the selective tumor localization of therapeutic radiation doses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams GP, DeNardo SJ, Deshpande SV, DeNardo GL, Meares CF, McCall MJ, Epstein AL (1989) Effect of mass of111Inbenzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Cancer Res 49:1707
Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo GL, Hellstrom I, Hellstrom KE (1992) Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antibody Immunoconjugates Radiopharm 5:81
Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford III WF, Bookman MA, Fand I, Houston LL, Weiner LM (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53:4026
Beaumier PL, Neuzil D, Yang H-M, Noll EA, Kishore R, Eary JF, Krohn KA, Nelp WJ, Hellstrom KE, Hellstrom J (1986) Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med 27:824
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242:423
Buchsbaum DJ, Langmuir VK, Wessels BW (1993) Experimental radioimmnotherapy. Med Phys 20:551
Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J (1990) In vivo tumor targeting of a recombinant single-chain antigenbinding protein, J Natl Cancer Inst 82: 1191
DeNardo GL, Krohn KA, DeNardo SJ (1977) Comparison of oncophilic radiopharmaceuticals,*I-fibrinogen,67Ga-citrate,111In-bleomycin and*I-bleomycin in tumor bearing mice. Cancer 40:2923
DeNardo SJ, Peng JS, DeNardo GL, Mills SM, Epstein AL (1986) Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Nucl Med Biol 13:303
Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inE. coli. Proc Natl Acad Sci USA 85:5879
Huston JS, McCartney JE, Tai M-S, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H (1993) Medical applications of single-chain antibodies. Antibody engineering. Medical applications. Int Rev Immunol 10:195
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227:680–85
McCartney JE, Tai M-S, Opperman H, Jin D, Warren FD, Weiner LM, Bookman MA, Stafford III WF, Houston LL, Huston JS (1993) Refolding of single-chain Fv With C-terminal cysteine (sFv'); formation of disulfide-bonded homodimers of anti-c-erbB-2 and anti-digoxin sFv'. Miami Short Rep 3:91
Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal jons. Anal Biochem 142:68
Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51:6363
Pack P, Pluckthun A (1992) Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity inEscherichia coli. Biochemistry 31:1579
Savage P, So A, Spooner RA, Epenetos AA (1993) A recombinant single-chain antibody interleukin-2 fusion protein. Br J Cancer 67:304
Tai M-S, Mudgett-Hunter M, Levinson D, Wu GM, Haber EA (1990) Bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain Fv. Biochemistry 29:8024
Weiner LM, Houston LL, Huston JS, McCartney JE, Tai M-S, Apell G, Stafford III WF, Bookman MA, Gallo J, Adams GP (In Press) Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Targeting
Wels W, Harwerth I-M, Mueller M, Groner B, Hynes NE (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52:6310
Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I (1993) A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94
Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433
Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402
Author information
Authors and Affiliations
Additional information
Supported by National Cancer Institute (NCI) National Cooperative Drug Discovery Group grant U01 CA51880, CA06927, an appropriation from the Commonwealth of Pennsylvania, and the Bernard A. and Rebecca S. Bernard Foundation
Rights and permissions
About this article
Cite this article
Adams, G.P., McCartney, J.E., Wolf, E.J. et al. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration. Cancer Immunol Immunother 40, 299–306 (1995). https://doi.org/10.1007/BF01519629
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01519629